$PHIO
Phio Pharmaceuticals Corp

2014 Q3 Form 10-Q Financial Statement

#000119312514309149 Filed on August 14, 2014

View on sec.gov

Income Statement

Concept 2014 Q3 2014 Q2 2013 Q2
Revenue $16.00K $12.00K $225.0K
YoY Change -82.61% -94.67%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $770.0K $850.0K -$11.27M
YoY Change -17.2% -107.54% -1665.28%
% of Gross Profit
Research & Development $1.459M $1.183M $1.213M
YoY Change 18.71% -2.47% -82.54%
% of Gross Profit
Depreciation & Amortization $30.00K $20.00K $20.00K
YoY Change 0.0% 0.0% -50.0%
% of Gross Profit
Operating Expenses $2.225M $2.033M $2.190M
YoY Change 2.87% -7.17% -71.42%
Operating Profit -$2.209M -$2.021M -$1.965M
YoY Change 6.66% 2.85% -74.36%
Interest Expense $4.000K $5.000K $4.000K
YoY Change -60.0% 25.0% -140.0%
% of Operating Profit
Other Income/Expense, Net $3.000K $15.00K $0.00
YoY Change 50.0% -100.0%
Pretax Income -$2.210M -$2.010M -$1.960M
YoY Change 7.28% 2.55% -74.21%
Income Tax $0.00 $0.00
% Of Pretax Income
Net Earnings -$2.206M -$2.006M -$1.961M
YoY Change 7.14% 2.29% -74.19%
Net Earnings / Revenue -13787.5% -16716.67% -871.56%
Basic Earnings Per Share
Diluted Earnings Per Share -$913.7M -$1.263B $1.325B
COMMON SHARES
Basic Shares Outstanding 16.10M shares 14.03M shares 338.2M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2014 Q3 2014 Q2 2013 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $10.13M $11.91M $17.59M
YoY Change -36.09% -32.29% 132.06%
Cash & Equivalents $5.130M $11.91M $8.587M
Short-Term Investments $5.000M $0.00 $9.000M
Other Short-Term Assets $560.0K $420.0K $260.0K
YoY Change 143.48% 61.54% 62.5%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $10.69M $12.33M $17.85M
YoY Change -33.52% -30.93% 130.61%
LONG-TERM ASSETS
Property, Plant & Equipment $193.0K $204.0K $147.0K
YoY Change 48.46% 38.78% -47.5%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $18.00K $18.00K $0.00
YoY Change
Total Long-Term Assets $211.0K $222.0K $147.0K
YoY Change 62.31% 51.02% -47.5%
TOTAL ASSETS
Total Short-Term Assets $10.69M $12.33M $17.85M
Total Long-Term Assets $211.0K $222.0K $147.0K
Total Assets $10.90M $12.55M $18.00M
YoY Change -32.76% -30.26% 124.39%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $137.0K $293.0K $358.0K
YoY Change -22.6% -18.16% 27.86%
Accrued Expenses $958.0K $682.0K $913.0K
YoY Change -5.89% -25.3% 49.67%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $0.00
YoY Change -100.0%
Total Short-Term Liabilities $1.156M $1.053M $1.510M
YoY Change -13.86% -30.26% 10.22%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change -100.0%
Other Long-Term Liabilities $0.00
YoY Change
Total Long-Term Liabilities $0.00 $0.00 $0.00
YoY Change -100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $1.156M $1.053M $1.510M
Total Long-Term Liabilities $0.00 $0.00 $0.00
Total Liabilities $1.160M $1.050M $1.510M
YoY Change -13.56% -30.46% 10.22%
SHAREHOLDERS EQUITY
Retained Earnings -$44.58M -$42.37M
YoY Change
Common Stock $2.000K $1.000K $1.000K
YoY Change 100.0% 0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $4.723M $6.562M $6.715M
YoY Change
Total Liabilities & Shareholders Equity $10.90M $12.55M $18.00M
YoY Change -32.76% -30.26% 124.39%

Cashflow Statement

Concept 2014 Q3 2014 Q2 2013 Q2
OPERATING ACTIVITIES
Net Income -$2.206M -$2.006M -$1.961M
YoY Change 7.14% 2.29% -74.19%
Depreciation, Depletion And Amortization $30.00K $20.00K $20.00K
YoY Change 0.0% 0.0% -50.0%
Cash From Operating Activities -$1.760M -$2.020M -$2.050M
YoY Change 1.73% -1.46% 41.38%
INVESTING ACTIVITIES
Capital Expenditures -$20.00K -$70.00K $0.00
YoY Change 100.0% -100.0%
Acquisitions
YoY Change
Other Investing Activities -$5.000M $3.010M -$9.000M
YoY Change -133.44%
Cash From Investing Activities -$5.010M $2.940M -$9.000M
YoY Change 50000.0% -132.67% 89900.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000 1.980M 10.00K
YoY Change -100.0% 19700.0% -99.88%
NET CHANGE
Cash From Operating Activities -1.760M -2.020M -2.050M
Cash From Investing Activities -5.010M 2.940M -9.000M
Cash From Financing Activities 0.000 1.980M 10.00K
Net Change In Cash -6.770M 2.900M -11.04M
YoY Change 286.86% -126.27% -253.12%
FREE CASH FLOW
Cash From Operating Activities -$1.760M -$2.020M -$2.050M
Capital Expenditures -$20.00K -$70.00K $0.00
Free Cash Flow -$1.740M -$1.950M -$2.050M
YoY Change 1.16% -4.88% 42.36%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2014Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
16103317 shares
CY2013Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
8587000
CY2014Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
14899159 shares
CY2014Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
1427676 shares
CY2014Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
14899159 shares
CY2014Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
3.41
CY2014Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2928932 shares
CY2014Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2014Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
3.41
CY2014Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
1500000000 shares
CY2014Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2014Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2014Q2 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2014Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
682000
CY2014Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
44586000
CY2014Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
293000
CY2014Q2 us-gaap Liabilities Current
LiabilitiesCurrent
1053000
CY2014Q2 us-gaap Stockholders Equity
StockholdersEquity
6562000
CY2014Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-42372000
CY2014Q2 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
78000
CY2014Q2 us-gaap Common Stock Value
CommonStockValue
1000
CY2014Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
12550000
CY2014Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2014Q2 us-gaap Assets Current
AssetsCurrent
12328000
CY2014Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
18000
CY2014Q2 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
50000
CY2014Q2 us-gaap Assets
Assets
12550000
CY2014Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
11911000
CY2014Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
415000
CY2014Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
367000
CY2014Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
780000
CY2014Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
204000
CY2012Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
5127000
CY2013Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
11788045 shares
CY2013Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
11788045 shares
CY2013Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
3.47
CY2013Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2556269 shares
CY2013Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2013Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
1500000000 shares
CY2013Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2013Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2013Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2013Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1795000
CY2013Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
40969000
CY2013Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
163000
CY2013Q4 us-gaap Liabilities Current
LiabilitiesCurrent
2076000
CY2013Q4 us-gaap Stockholders Equity
StockholdersEquity
4942000
CY2013Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-38082000
CY2013Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
118000
CY2013Q4 us-gaap Common Stock Value
CommonStockValue
1000
CY2013Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
14938000
CY2013Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2013Q4 us-gaap Assets Current
AssetsCurrent
14743000
CY2013Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
18000
CY2013Q4 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
50000
CY2013Q4 us-gaap Assets
Assets
14938000
CY2013Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
11390000
CY2013Q4 us-gaap Short Term Investments
ShortTermInvestments
3000000
CY2013Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
303000
CY2013Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
177000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0125 pure
us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
0 shares
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y11M1D
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
8845026 shares
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-3184000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
3.90
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.0000 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
0.7553 pure
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
26370423 shares
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-5000
us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
9000000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-22304000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-3000
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
4000
us-gaap Revenue From Grants
RevenueFromGrants
278000
us-gaap Operating Income Loss
OperatingIncomeLoss
-16359000
us-gaap Net Income Loss
NetIncomeLoss
-16358000
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-2.52
us-gaap Repayments Of Long Term Capital Lease Obligations
RepaymentsOfLongTermCapitalLeaseObligations
5000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
2000
us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
44000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1652000
us-gaap Research And Development Asset Acquired Other Than Through Business Combination Written Off
ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff
12250000
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
15646000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-279000
us-gaap Share Based Compensation
ShareBasedCompensation
1057000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
3460000
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-9002000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
146000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-58000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
15651000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
14985000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
53000
us-gaap Preferred Stock Dividends And Other Adjustments
PreferredStockDividendsAndOtherAdjustments
5946000
us-gaap Operating Expenses
OperatingExpenses
16637000
dei Entity Registrant Name
EntityRegistrantName
RXi Pharmaceuticals Corp
dei Amendment Flag
AmendmentFlag
false
dei Entity Filer Category
EntityFilerCategory
Smaller Reporting Company
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2014
dei Document Type
DocumentType
10-Q
dei Document Period End Date
DocumentPeriodEndDate
2014-06-30
dei Entity Central Index Key
EntityCentralIndexKey
0001533040
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0191 pure
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
shares
us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
0 shares
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y3M26D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y2M12D
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
13319634 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
3.00
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-4397000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
2.42
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.0000 pure
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.54
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
372663 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
1.0095 pure
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P8Y15D
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
25559710 shares
us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"> <i>Uses of estimates in preparation of financial statements</i></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"> The preparation of financial statements in accordance with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from these estimates.</p> </div>
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
64000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-7258000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
10000
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
11000
us-gaap Revenue From Grants
RevenueFromGrants
41000
us-gaap Operating Income Loss
OperatingIncomeLoss
-4311000
us-gaap Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
10000
us-gaap Net Income Loss
NetIncomeLoss
-4290000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
71000
us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
46600
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1693000
us-gaap Proceeds From Sale Maturity And Collections Of Investments
ProceedsFromSaleMaturityAndCollectionsOfInvestments
3000000
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
1977000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-40000
us-gaap Share Based Compensation
ShareBasedCompensation
948000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
521000
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
2941000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-1113000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
130000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
1947000
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
12000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2659000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
42000
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
30000
us-gaap Preferred Stock Dividends And Other Adjustments
PreferredStockDividendsAndOtherAdjustments
2968000
us-gaap Operating Expenses
OperatingExpenses
4352000
CY2013Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0125 pure
CY2013Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y11M1D
CY2013Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
11168144 shares
CY2013Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
3.90
CY2013Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.0000 pure
CY2013Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.39
CY2013Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
0.7553 pure
CY2013Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-4360000
CY2013Q2 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
4000
CY2013Q2 us-gaap Revenue From Grants
RevenueFromGrants
225000
CY2013Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-1965000
CY2013Q2 us-gaap Net Income Loss
NetIncomeLoss
-1961000
CY2013Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
977000
CY2013Q2 us-gaap Share Based Compensation
ShareBasedCompensation
429000
CY2013Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1213000
CY2013Q2 us-gaap Preferred Stock Dividends And Other Adjustments
PreferredStockDividendsAndOtherAdjustments
2399000
CY2013Q2 us-gaap Operating Expenses
OperatingExpenses
2190000
CY2013Q2 rxii Issuance Of Stock Options For Services
IssuanceOfStockOptionsForServices
8400
CY2014Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0185 pure
CY2014Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y11M16D
CY2014Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
14015451 shares
CY2014Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
2.26
CY2014Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.0000 pure
CY2014Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.23
CY2014Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
1.0077 pure
CY2014Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-3219000
CY2014Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
10000
CY2014Q2 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
5000
CY2014Q2 us-gaap Revenue From Grants
RevenueFromGrants
12000
CY2014Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-2021000
CY2014Q2 us-gaap Net Income Loss
NetIncomeLoss
-2006000
CY2014Q2 us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
9600
CY2014Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
850000
CY2014Q2 us-gaap Share Based Compensation
ShareBasedCompensation
457000
CY2014Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1183000
CY2014Q2 us-gaap Preferred Stock Dividends And Other Adjustments
PreferredStockDividendsAndOtherAdjustments
1213000
CY2014Q2 us-gaap Operating Expenses
OperatingExpenses
2033000

Files In Submission

Name View Source Status
0001193125-14-309149-index-headers.html Edgar Link pending
0001193125-14-309149-index.html Edgar Link pending
0001193125-14-309149.txt Edgar Link pending
0001193125-14-309149-xbrl.zip Edgar Link pending
d754084d10q.htm Edgar Link pending
d754084dex311.htm Edgar Link pending
d754084dex321.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xls Edgar Link pending
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
rxii-20140630.xml Edgar Link completed
rxii-20140630.xsd Edgar Link pending
rxii-20140630_cal.xml Edgar Link unprocessable
rxii-20140630_def.xml Edgar Link unprocessable
rxii-20140630_lab.xml Edgar Link unprocessable
rxii-20140630_pre.xml Edgar Link unprocessable
Show.js Edgar Link pending